TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer

BACKGROUND: In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is associated with estrogen-independent tumor growth and resistance to endocrine therapies. This study investigated whether the addition of bevacizumab, a monocl...

Full description

Saved in:
Bibliographic Details
Published in:Breast Cancer Res
Main Authors: Vaklavas, Christos, Roberts, Brian S., Varley, Katherine E., Lin, Nancy U., Liu, Minetta C., Rugo, Hope S., Puhalla, Shannon, Nanda, Rita, Storniolo, Anna Maria, Carey, Lisa A., Saleh, Mansoor N., Li, Yufeng, Delossantos, Jennifer F., Grizzle, William E., LoBuglio, Albert F., Myers, Richard M., Forero-Torres, Andres
Format: Artigo
Language:Inglês
Published: BioMed Central 2020
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7027068/
https://ncbi.nlm.nih.gov/pubmed/32070401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-020-01258-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items